1. Home
  2. BLKB vs DMRA Comparison

BLKB vs DMRA Comparison

Compare BLKB & DMRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Blackbaud Inc.

BLKB

Blackbaud Inc.

HOLD

Current Price

$41.89

Market Cap

1.5B

Sector

Technology

ML Signal

HOLD

DMRA

Damora Therapeutics Inc. Common Stock

N/A

Current Price

$28.50

Market Cap

1.5B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
BLKB
DMRA
Founded
1981
2011
Country
United States
United States
Employees
N/A
7
Industry
Computer Software: Prepackaged Software
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.5B
1.5B
IPO Year
2004
2020

Fundamental Metrics

Financial Performance
Metric
BLKB
DMRA
Price
$41.89
$28.50
Analyst Decision
Hold
Buy
Analyst Count
3
2
Target Price
$50.00
$43.00
AVG Volume (30 Days)
673.6K
501.3K
Earning Date
04-29-2026
05-11-2026
Dividend Yield
N/A
N/A
EPS Growth
142.32
N/A
EPS
1.46
N/A
Revenue
N/A
N/A
Revenue This Year
$6.26
N/A
Revenue Next Year
$4.25
N/A
P/E Ratio
$62.96
N/A
Revenue Growth
N/A
N/A
52 Week Low
$25.58
$16.50
52 Week High
$70.71
$34.89

Technical Indicators

Market Signals
Indicator
BLKB
DMRA
Relative Strength Index (RSI) 80.48 51.17
Support Level $34.65 $22.71
Resistance Level $64.76 $34.89
Average True Range (ATR) 2.08 2.50
MACD 1.04 -0.42
Stochastic Oscillator 97.23 27.91

Price Performance

Historical Comparison
BLKB
DMRA

About BLKB Blackbaud Inc.

Founded in 1981, Blackbaud provides software solutions designed to serve the "social good" community, including nonprofits, foundations, corporations, educational institutions, healthcare institutions, and individual change agents. Through M&A and organic product development efforts, the company has also moved into related areas outside core fundraising, notably into K-12 schools. The firm enables more than $100 billion in donations annually across a customer base in excess of 40,000 customers in over 100 countries.

About DMRA Damora Therapeutics Inc. Common Stock

Damora Therapeutics Inc is a biotechnology company that aims to fundamentally redefine care for people with hematologic disorders. The group is advancing a new generation of biologics to treat mutant calreticulin-driven myeloproliferative neoplasms, including essential thrombocythemia and myelofibrosis, where there is cruicial medical need for disease-modifying treatments. Its goal is to rapidly bring forward optimized therapies with broad mutation coverage and exceptional convenience to dramatically improve patient outcomes. The group's pipeline products are DMR-001, DMR-002, DMR-003, and GB3226.

Share on Social Networks: